SNCA and Parkinson disease: Targeting C-terminal truncations could be a viable strategy in Parkinson's disease therapeutic research, as this α-synuclein modification has been observed to be present in Lewy bodies, to accelerate aggregation in vitro and in vivo, and to enhance prion-like spreading in Parkinson's disease models (124, 125, 208, 292).